{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:06:04Z","timestamp":1753877164316,"version":"3.41.2"},"reference-count":16,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Backgrounds<\/jats:title>\n                  <jats:p>S-1 plus oxaliplatin appears effective in chemo-na\u00efve patients with advanced gastric cancer. However, comprehensive safety and efficacy data for S-1 plus oxaliplatin is limited for patients with impaired renal function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively extracted data from advanced gastric cancer patients with normal renal function (normal group, CLcr \u2265 60\u00a0ml\/min), who were treated with standard doses of S-1 (80\u00a0mg\/m2) plus oxaliplatin (100\u00a0mg\/m2), and patients with impaired renal function (impaired group, CLcr &lt; 60\u00a0ml\/min) who were treated with standard or reduced doses of S-1 (60\u00a0mg\/m2 or 40\u00a0mg\/m2) plus standard doses of oxaliplatin. Treatment efficacy and safety between the groups were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 100 normal patients and 42 patients with impaired renal function were extracted. Baseline characteristics differed significantly between the two groups, including age (median, 64 vs 72\u00a0years, P\u00a0&lt;\u00a00.0001) and body surface area (median, 1.68 vs 1.51\u00a0m2, P\u00a0&lt;\u00a00.0001). In the impaired group, 66.6% (28\/42) started with a reduced dose. Within the impaired group, more patients had a reduced initial S-1 dose when CLcr &lt;50\u00a0ml\/min (77.3%). The median progression-free and overall survival between the normal and impaired groups was 6.1 vs 5.7\u00a0months (P\u00a0=\u00a00.698) and 16.1 vs 18.5\u00a0months (P\u00a0=\u00a00.638), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>S-1 plus oxaliplatin in advanced gastric cancer patients with impaired renal function appears safe and has demonstrated efficacy given appropriate dose modification.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyz157","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T15:27:16Z","timestamp":1569943636000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study"],"prefix":"10.1093","author":[{"given":"Ken","family":"Demachi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya"},{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanaga","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikatsu","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"article-title":"GLOBOCAN","year":"2012","author":"International Agency for Research on Cancer","key":"2019110610060263700_ref1"},{"author":"Cancer Registry and Statistics","key":"2019110610060263700_ref2"},{"author":"Ministry of Health","key":"2019110610060263700_ref3"},{"key":"2019110610060263700_ref4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jjco\/hyv088","article-title":"Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project","volume":"45","author":"Hori","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2019110610060263700_ref5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/annonc\/mdh078","article-title":"Evaluation of renal function in elderly cancer patients","volume":"15","author":"Monfardini","year":"2004","journal-title":"Ann Oncol"},{"key":"2019110610060263700_ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"key":"2019110610060263700_ref7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","article-title":"Development of a novel from of an oral 5-fluorouracil derivative (S-1) directed to the epotentiation tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators","volume":"7","author":"Shirasaka","year":"1996","journal-title":"Anticancer Drugs"},{"key":"2019110610060263700_ref8","first-page":"4004","article-title":"Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats","volume":"53","author":"Shirasaka","year":"1993","journal-title":"Cancer Res"},{"key":"2019110610060263700_ref9","first-page":"2000","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug","volume":"5","author":"Hirata","year":"1995","journal-title":"Clin Cancer Res"},{"key":"2019110610060263700_ref10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-002-0457-z","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function","volume":"50","author":"Ikeda","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019110610060263700_ref11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cas.12044","article-title":"Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer","volume":"104","author":"Kim","year":"2013","journal-title":"Cancer Sci"},{"key":"2019110610060263700_ref12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00280-007-0595-4","article-title":"Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients","volume":"61","author":"Yamanaka","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"author":"Taiho Pharmaceutical","key":"2019110610060263700_ref13"},{"key":"2019110610060263700_ref14","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of Oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019110610060263700_ref15","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-07-0475","article-title":"Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function","volume":"13","author":"Takimoto","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019110610060263700_ref16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyz157\/30438830\/hyz157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyz157\/30438830\/hyz157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T10:06:13Z","timestamp":1573034773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyz157\/5613906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz157","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"article-number":"hyz157"}}